Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Macrophage nuclear receptors: Emerging key players in infectious diseases.

Leopold Wager CM, Arnett E, Schlesinger LS.

PLoS Pathog. 2019 Mar 21;15(3):e1007585. doi: 10.1371/journal.ppat.1007585. eCollection 2019 Mar. Review.

2.

l-Arginine Synthesis from l-Citrulline in Myeloid Cells Drives Host Defense against Mycobacteria In Vivo.

Lange SM, McKell MC, Schmidt SM, Zhao J, Crowther RR, Green LC, Bricker RL, Arnett E, Köhler SE, Schlesinger LS, Setchell KDR, Qualls JE.

J Immunol. 2019 Mar 15;202(6):1747-1754. doi: 10.4049/jimmunol.1801569. Epub 2019 Feb 1.

PMID:
30710047
3.

Protein Interaction Mapping Identifies RBBP6 as a Negative Regulator of Ebola Virus Replication.

Batra J, Hultquist JF, Liu D, Shtanko O, Von Dollen J, Satkamp L, Jang GM, Luthra P, Schwarz TM, Small GI, Arnett E, Anantpadma M, Reyes A, Leung DW, Kaake R, Haas P, Schmidt CB, Schlesinger LS, LaCount DJ, Davey RA, Amarasinghe GK, Basler CF, Krogan NJ.

Cell. 2018 Dec 13;175(7):1917-1930.e13. doi: 10.1016/j.cell.2018.08.044.

PMID:
30550789
4.

Diabetes screen during tuberculosis contact investigations highlights opportunity for new diabetes diagnosis and reveals metabolic differences between ethnic groups.

Restrepo BI, Kleynhans L, Salinas AB, Abdelbary B, Tshivhula H, Aguillón-Durán GP, Kunsevi-Kilola C, Salinas G, Stanley K, Malherbe ST, Maasdorp E, Garcia-Viveros M, Louw I, Garcia-Oropesa EM, Lopez-Alvarenga JC, Prins JB, Walzl G, Schlesinger LS, Ronacher K.

Tuberculosis (Edinb). 2018 Dec;113:10-18. doi: 10.1016/j.tube.2018.08.007. Epub 2018 Aug 18.

5.

AR-13 reduces antibiotic-resistant bacterial burden in cystic fibrosis phagocytes and improves cystic fibrosis transmembrane conductance regulator function.

Assani K, Shrestha CL, Rinehardt H, Zhang S, Robledo-Avila F, Wellmerling J, Partida-Sanchez S, Cormet-Boyaka E, Reynolds SD, Schlesinger LS, Kopp BT.

J Cyst Fibros. 2018 Oct 23. pii: S1569-1993(18)30869-5. doi: 10.1016/j.jcf.2018.10.010. [Epub ahead of print]

PMID:
30366849
6.

IL-13-regulated Macrophage Polarization during Granuloma Formation in an In Vitro Human Sarcoidosis Model.

Locke LW, Crouser ED, White P, Julian MW, Caceres EG, Papp AC, Le VT, Sadee W, Schlesinger LS.

Am J Respir Cell Mol Biol. 2019 Jan;60(1):84-95. doi: 10.1165/rcmb.2018-0053OC.

PMID:
30134122
7.

Deletion of PPARγ in lung macrophages provides an immunoprotective response against M. tuberculosis infection in mice.

Guirado E, Rajaram MV, Chawla A, Daigle J, La Perle KM, Arnett E, Turner J, Schlesinger LS.

Tuberculosis (Edinb). 2018 Jul;111:170-177. doi: 10.1016/j.tube.2018.06.012. Epub 2018 Jun 21.

8.

PPARγ is critical for Mycobacterium tuberculosis induction of Mcl-1 and limitation of human macrophage apoptosis.

Arnett E, Weaver AM, Woodyard KC, Montoya MJ, Li M, Hoang KV, Hayhurst A, Azad AK, Schlesinger LS.

PLoS Pathog. 2018 Jun 21;14(6):e1007100. doi: 10.1371/journal.ppat.1007100. eCollection 2018 Jun.

9.

AmpliSeq transcriptome analysis of human alveolar and monocyte-derived macrophages over time in response to Mycobacterium tuberculosis infection.

Papp AC, Azad AK, Pietrzak M, Williams A, Handelman SK, Igo RP Jr, Stein CM, Hartmann K, Schlesinger LS, Sadee W.

PLoS One. 2018 May 30;13(5):e0198221. doi: 10.1371/journal.pone.0198221. eCollection 2018.

10.

Complement Receptor 3-Mediated Inhibition of Inflammasome Priming by Ras GTPase-Activating Protein During Francisella tularensis Phagocytosis by Human Mononuclear Phagocytes.

Hoang KV, Rajaram MVS, Curry HM, Gavrilin MA, Wewers MD, Schlesinger LS.

Front Immunol. 2018 Mar 26;9:561. doi: 10.3389/fimmu.2018.00561. eCollection 2018.

11.

Use of a leukocyte-targeted peptide probe as a potential tracer for imaging the tuberculosis granuloma.

Locke LW, Kothandaraman S, Tweedle M, Chaney S, Wozniak DJ, Schlesinger LS.

Tuberculosis (Edinb). 2018 Jan;108:201-210. doi: 10.1016/j.tube.2018.01.001. Epub 2018 Jan 8.

12.

Mycobacterium abscessus Smooth and Rough Morphotypes Form Antimicrobial-Tolerant Biofilm Phenotypes but Are Killed by Acetic Acid.

Clary G, Sasindran SJ, Nesbitt N, Mason L, Cole S, Azad A, McCoy K, Schlesinger LS, Hall-Stoodley L.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01782-17. doi: 10.1128/AAC.01782-17. Print 2018 Mar.

13.

O-Mannosylation of Proteins Enables Histoplasma Yeast Survival at Mammalian Body Temperatures.

Garfoot AL, Goughenour KD, Wüthrich M, Rajaram MVS, Schlesinger LS, Klein BS, Rappleye CA.

MBio. 2018 Jan 2;9(1). pii: e02121-17. doi: 10.1128/mBio.02121-17.

14.

Elemental Ingredients in the Macrophage Cocktail: Role of ZIP8 in Host Response to Mycobacterium tuberculosis.

Pyle CJ, Azad AK, Papp AC, Sadee W, Knoell DL, Schlesinger LS.

Int J Mol Sci. 2017 Nov 9;18(11). pii: E2375. doi: 10.3390/ijms18112375. Review.

15.

Alveolar macrophages from tuberculosis patients display an altered inflammatory gene expression profile.

Lavalett L, Rodriguez H, Ortega H, Sadee W, Schlesinger LS, Barrera LF.

Tuberculosis (Edinb). 2017 Dec;107:156-167. doi: 10.1016/j.tube.2017.08.012. Epub 2017 Sep 18.

PMID:
29050765
16.

Cysteamine-mediated clearance of antibiotic-resistant pathogens in human cystic fibrosis macrophages.

Shrestha CL, Assani KD, Rinehardt H, Albastroiu F, Zhang S, Shell R, Amer AO, Schlesinger LS, Kopp BT.

PLoS One. 2017 Oct 5;12(10):e0186169. doi: 10.1371/journal.pone.0186169. eCollection 2017.

17.

M. tuberculosis-Initiated Human Mannose Receptor Signaling Regulates Macrophage Recognition and Vesicle Trafficking by FcRγ-Chain, Grb2, and SHP-1.

Rajaram MVS, Arnett E, Azad AK, Guirado E, Ni B, Gerberick AD, He LZ, Keler T, Thomas LJ, Lafuse WP, Schlesinger LS.

Cell Rep. 2017 Oct 3;21(1):126-140. doi: 10.1016/j.celrep.2017.09.034.

18.

AR-13, a Celecoxib Derivative, Directly Kills Francisella In Vitro and Aids Clearance and Mouse Survival In Vivo.

Hoang KV, Adcox HE, Fitch JR, Gordon DM, Curry HM, Schlesinger LS, White P, Gunn JS.

Front Microbiol. 2017 Sep 11;8:1695. doi: 10.3389/fmicb.2017.01695. eCollection 2017.

19.

Human Genetic Determinants of Viral Diseases.

Kenney AD, Dowdle JA, Bozzacco L, McMichael TM, St Gelais C, Panfil AR, Sun Y, Schlesinger LS, Anderson MZ, Green PL, López CB, Rosenberg BR, Wu L, Yount JS.

Annu Rev Genet. 2017 Nov 27;51:241-263. doi: 10.1146/annurev-genet-120116-023425. Epub 2017 Aug 30. Review.

20.

PO and ID BCG vaccination in humans induce distinct mucosal and systemic immune responses and CD4+ T cell transcriptomal molecular signatures.

Hoft DF, Xia M, Zhang GL, Blazevic A, Tennant J, Kaplan C, Matuschak G, Dube TJ, Hill H, Schlesinger LS, Andersen PL, Brusic V.

Mucosal Immunol. 2018 Mar;11(2):486-495. doi: 10.1038/mi.2017.67. Epub 2017 Aug 30.

21.

A Novel In Vitro Human Granuloma Model of Sarcoidosis and Latent Tuberculosis Infection.

Crouser ED, White P, Caceres EG, Julian MW, Papp AC, Locke LW, Sadee W, Schlesinger LS.

Am J Respir Cell Mol Biol. 2017 Oct;57(4):487-498. doi: 10.1165/rcmb.2016-0321OC.

22.

The Mycobacterium tuberculosis MmpL11 Cell Wall Lipid Transporter Is Important for Biofilm Formation, Intracellular Growth, and Nonreplicating Persistence.

Wright CC, Hsu FF, Arnett E, Dunaj JL, Davidson PM, Pacheco SA, Harriff MJ, Lewinsohn DM, Schlesinger LS, Purdy GE.

Infect Immun. 2017 Jul 19;85(8). pii: e00131-17. doi: 10.1128/IAI.00131-17. Print 2017 Aug.

23.

Defining a Research Agenda to Address the Converging Epidemics of Tuberculosis and Diabetes: Part 2: Underlying Biologic Mechanisms.

Ronacher K, van Crevel R, Critchley JA, Bremer AA, Schlesinger LS, Kapur A, Basaraba R, Kornfeld H, Restrepo BI.

Chest. 2017 Jul;152(1):174-180. doi: 10.1016/j.chest.2017.02.032. Epub 2017 Apr 20. Review.

24.

Defining a Research Agenda to Address the Converging Epidemics of Tuberculosis and Diabetes: Part 1: Epidemiology and Clinical Management.

Critchley JA, Restrepo BI, Ronacher K, Kapur A, Bremer AA, Schlesinger LS, Basaraba R, Kornfeld H, van Crevel R.

Chest. 2017 Jul;152(1):165-173. doi: 10.1016/j.chest.2017.04.155. Epub 2017 Apr 20. Review.

25.

Integrating Lung Physiology, Immunology, and Tuberculosis.

Torrelles JB, Schlesinger LS.

Trends Microbiol. 2017 Aug;25(8):688-697. doi: 10.1016/j.tim.2017.03.007. Epub 2017 Mar 30. Review.

26.

New concepts in understanding latent tuberculosis.

Dodd CE, Schlesinger LS.

Curr Opin Infect Dis. 2017 Jun;30(3):316-321. doi: 10.1097/QCO.0000000000000367. Review.

PMID:
28177961
27.

Human Cystic Fibrosis Macrophages Have Defective Calcium-Dependent Protein Kinase C Activation of the NADPH Oxidase, an Effect Augmented by Burkholderia cenocepacia.

Assani K, Shrestha CL, Robledo-Avila F, Rajaram MV, Partida-Sanchez S, Schlesinger LS, Kopp BT.

J Immunol. 2017 Mar 1;198(5):1985-1994. doi: 10.4049/jimmunol.1502609. Epub 2017 Jan 16.

28.

Innate Immune Responses to Tuberculosis.

Schorey JS, Schlesinger LS.

Microbiol Spectr. 2016 Dec;4(6). doi: 10.1128/microbiolspec.TBTB2-0010-2016. Review.

PMID:
28087945
29.

Zinc Modulates Endotoxin-Induced Human Macrophage Inflammation through ZIP8 Induction and C/EBPβ Inhibition.

Pyle CJ, Akhter S, Bao S, Dodd CE, Schlesinger LS, Knoell DL.

PLoS One. 2017 Jan 5;12(1):e0169531. doi: 10.1371/journal.pone.0169531. eCollection 2017.

30.

CD36-Mediated Uptake of Surfactant Lipids by Human Macrophages Promotes Intracellular Growth of Mycobacterium tuberculosis.

Dodd CE, Pyle CJ, Glowinski R, Rajaram MV, Schlesinger LS.

J Immunol. 2016 Dec 15;197(12):4727-4735. Epub 2016 Nov 9.

31.

Corrigendum to the inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach [Nucl Med Biol 43 (2016) 215-225].

Cope FO, Abbruzzese B, Sanders J, Metz W, Sturms K, Ralph D, Blue M, Zhang J, Bracci P, Bshara W, Behr S, Maurer T, Williams K, Walker J, Beverly A, Blay B, Damughatla A, Larsen M, Mountain C, Neylon E, Parcel K, Raghuraman K, Ricks K, Rose L, Sivakumar A, Streck N, Wang B, Wasco C, Williams A, Schlesinger LS, Azad A, Rajaram MVS, Jarjour W, Young N, Rosol T, McGrath M.

Nucl Med Biol. 2016 Dec;43(12):837. doi: 10.1016/j.nucmedbio.2016.10.001. No abstract available.

PMID:
27866590
32.

Human isotype-dependent inhibitory antibody responses against Mycobacterium tuberculosis.

Zimmermann N, Thormann V, Hu B, Köhler AB, Imai-Matsushima A, Locht C, Arnett E, Schlesinger LS, Zoller T, Schürmann M, Kaufmann SH, Wardemann H.

EMBO Mol Med. 2016 Nov 2;8(11):1325-1339. doi: 10.15252/emmm.201606330. Print 2016 Nov.

33.

Elevated Mirc1/Mir17-92 cluster expression negatively regulates autophagy and CFTR (cystic fibrosis transmembrane conductance regulator) function in CF macrophages.

Tazi MF, Dakhlallah DA, Caution K, Gerber MM, Chang SW, Khalil H, Kopp BT, Ahmed AE, Krause K, Davis I, Marsh C, Lovett-Racke AE, Schlesinger LS, Cormet-Boyaka E, Amer AO.

Autophagy. 2016 Nov;12(11):2026-2037.

34.

Cardiac Electrical and Structural Changes During Bacterial Infection: An Instructive Model to Study Cardiac Dysfunction in Sepsis.

Makara MA, Hoang KV, Ganesan LP, Crouser ED, Gunn JS, Turner J, Schlesinger LS, Mohler PJ, Rajaram MV.

J Am Heart Assoc. 2016 Sep 12;5(9). pii: e003820. doi: 10.1161/JAHA.116.003820.

35.

Targeting CBLB as a potential therapeutic approach for disseminated candidiasis.

Xiao Y, Tang J, Guo H, Zhao Y, Tang R, Ouyang S, Zeng Q, Rappleye CA, Rajaram MV, Schlesinger LS, Tao L, Brown GD, Langdon WY, Li BT, Zhang J.

Nat Med. 2016 Aug;22(8):906-14. doi: 10.1038/nm.4141. Epub 2016 Jul 18.

36.

Modeling Granulomas in Response to Infection in the Lung.

Hao W, Schlesinger LS, Friedman A.

PLoS One. 2016 Mar 17;11(3):e0148738. doi: 10.1371/journal.pone.0148738. eCollection 2016.

37.

Correction: Fine Tuning Inflammation at the Front Door: Macrophage Complement Receptor 3-mediates Phagocytosis and Immune Suppression for Francisella tularensis.

Dai S, Rajaram MV, Curry HM, Leander R, Schlesinger LS.

PLoS Pathog. 2016 Mar 9;12(3):e1005504. doi: 10.1371/journal.ppat.1005504. eCollection 2016 Mar. No abstract available.

38.

The inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach.

Cope FO, Abbruzzese B, Sanders J, Metz W, Sturms K, Ralph D, Blue M, Zhang J, Bracci P, Bshara W, Behr S, Maurer T, Williams K, Walker J, Beverly A, Blay B, Damughatla A, Larsen M, Mountain C, Neylon E, Parcel K, Raghuraman K, Ricks K, Rose L, Sivakumar A, Streck N, Wang B, Wasco C, Schlesinger LS, Azad A, Rajaram MVS, Jarjour W, Young N, Rosol T, Williams A, McGrath M.

Nucl Med Biol. 2016 Mar;43(3):215-25. doi: 10.1016/j.nucmedbio.2015.11.007. Epub 2015 Dec 3. Review. Erratum in: Nucl Med Biol. 2016 Dec;43(12):837.

39.

Needle-Free Delivery of Acetalated Dextran-Encapsulated AR-12 Protects Mice from Francisella tularensis Lethal Challenge.

Hoang KV, Curry H, Collier MA, Borteh H, Bachelder EM, Schlesinger LS, Gunn JS, Ainslie KM.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2052-62. doi: 10.1128/AAC.02228-15. Print 2016 Apr.

40.

γ-Tilmanocept, a New Radiopharmaceutical Tracer for Cancer Sentinel Lymph Nodes, Binds to the Mannose Receptor (CD206).

Azad AK, Rajaram MV, Metz WL, Cope FO, Blue MS, Vera DR, Schlesinger LS.

J Immunol. 2015 Sep 1;195(5):2019-29. doi: 10.4049/jimmunol.1402005. Epub 2015 Jul 22.

41.

Toward Resolving the Paradox of the Critical Role of the DosR Regulon in Mycobacterium tuberculosis Persistence and Active Disease.

Voskuil MI, Schlesinger LS.

Am J Respir Crit Care Med. 2015 May 15;191(10):1103-5. doi: 10.1164/rccm.201503-0424ED. No abstract available.

PMID:
25978571
42.

Identification of OprF as a complement component C3 binding acceptor molecule on the surface of Pseudomonas aeruginosa.

Mishra M, Ressler A, Schlesinger LS, Wozniak DJ.

Infect Immun. 2015 Aug;83(8):3006-14. doi: 10.1128/IAI.00081-15. Epub 2015 May 11.

43.

Design and synthesis of novel anti-tuberculosis agents from the celecoxib pharmacophore.

Salunke SB, Azad AK, Kapuriya NP, Balada-Llasat JM, Pancholi P, Schlesinger LS, Chen CS.

Bioorg Med Chem. 2015 May 1;23(9):1935-43. doi: 10.1016/j.bmc.2015.03.041. Epub 2015 Mar 20.

PMID:
25818768
44.

Role for NOD2 in Mycobacterium tuberculosis-induced iNOS expression and NO production in human macrophages.

Landes MB, Rajaram MV, Nguyen H, Schlesinger LS.

J Leukoc Biol. 2015 Jun;97(6):1111-9. doi: 10.1189/jlb.3A1114-557R. Epub 2015 Mar 23.

45.

Characterization of host and microbial determinants in individuals with latent tuberculosis infection using a human granuloma model.

Guirado E, Mbawuike U, Keiser TL, Arcos J, Azad AK, Wang SH, Schlesinger LS.

MBio. 2015 Feb 17;6(1):e02537-14. doi: 10.1128/mBio.02537-14.

46.
47.

Macrophage immunoregulatory pathways in tuberculosis.

Rajaram MV, Ni B, Dodd CE, Schlesinger LS.

Semin Immunol. 2014 Dec;26(6):471-85. doi: 10.1016/j.smim.2014.09.010. Epub 2014 Oct 30. Review.

48.

Acetalated dextran encapsulated AR-12 as a host-directed therapy to control Salmonella infection.

Hoang KV, Borteh HM, Rajaram MV, Peine KJ, Curry H, Collier MA, Homsy ML, Bachelder EM, Gunn JS, Schlesinger LS, Ainslie KM.

Int J Pharm. 2014 Dec 30;477(1-2):334-43. doi: 10.1016/j.ijpharm.2014.10.022. Epub 2014 Oct 22.

49.

The global one health paradigm: challenges and opportunities for tackling infectious diseases at the human, animal, and environment interface in low-resource settings.

Gebreyes WA, Dupouy-Camet J, Newport MJ, Oliveira CJ, Schlesinger LS, Saif YM, Kariuki S, Saif LJ, Saville W, Wittum T, Hoet A, Quessy S, Kazwala R, Tekola B, Shryock T, Bisesi M, Patchanee P, Boonmar S, King LJ.

PLoS Negl Trop Dis. 2014 Nov 13;8(11):e3257. doi: 10.1371/journal.pntd.0003257. eCollection 2014. Review.

50.

Chemoproteomics reveals Toll-like receptor fatty acylation.

Chesarino NM, Hach JC, Chen JL, Zaro BW, Rajaram MV, Turner J, Schlesinger LS, Pratt MR, Hang HC, Yount JS.

BMC Biol. 2014 Nov 5;12:91. doi: 10.1186/s12915-014-0091-3.

Supplemental Content

Loading ...
Support Center